Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy
Diabetes/Metabolism Research and Reviews · 2025-10 · 41 (7)
DOI: 10.1002/dmrr.70091 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 09.10.2025. Verfasst von Aaron W Michels und 3 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Immunotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Sanofi.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Disease‐modifying therapies have been used to treat the underlying causes of autoimmune diseases for over half a century. However, until recently, type 1 diabetes (T1D), the autoimmune form of diabetes, had not entered this therapeutic landscape. The approval of teplizumab, an anti‐CD3 monoclonal antibody and the first disease‐modifying therapy for use in individuals with preclinical T1D, has caused a major shift in the way healthcare providers can treat the T1D disease course. In this review, we discuss the chronic autoimmune nature of T1D and provide an overview of disease‐modifying therapies that are under investigation to target the autoimmune mechanisms in T1D to preserve residual beta‐cell function and prevent disease progression. The considerations for implementing these therapies into clinical practice are also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Children's Hospital of Richmond, Virginia Commonwealth University, Richmond, Virginia, USA.
- Cardiff University, Cardiff, UK.
Förderung
- NIDDK NIH HHS
- Sanofi
Zitieren
APA
Michels, A. W., Gottlieb, P. A., Nelson, B., & Dayan, C. (2025). Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy. Diabetes/Metabolism Research and Reviews, 41(7). https://doi.org/10.1002/dmrr.70091
Vancouver
Michels AW, Gottlieb PA, Nelson B, Dayan C. Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy. Diabetes/Metabolism Research and Reviews. 2025;41(7). doi:10.1002/dmrr.70091
BibTeX
@article{Michels2025,
author = {Michels, Aaron W and Gottlieb, Peter A and Nelson, Bryce and Dayan, Colin},
title = {Autoimmune Type 1 Diabetes in the Era of Disease‐Modifying Immune Therapy},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2025},
volume = {41},
number = {7},
doi = {10.1002/dmrr.70091}
}
EUVIMED